Mechanistic insights into the inhibition of Prostate-Specific Antigen (PSA) by ÃŸ-lactam class compounds
Proteins: Structure, Functions, & Bioinformatics
A Prostate-Specific Antigen (PSA)-activated HPMA copolymer prodrug as dual-targeted therapy for prostate cancer
Molecular Cancer Therapeutics
Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint
Cancer Biology & Therapy
A prostate-specific antigen-activated channel forming toxin as therapy for prostatic disease
Journal of the National Cancer Institute
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Synthesis and screening of a random dimeric peptide library using one-Bead-one dimer combinatorial approach
Prospective, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Phase IIb Clinical Trial of the Pore-Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia.
J. Urol., Nov (2012)
The unfolding treatment landscape for men with castration-resistant prostate cancer.
Clin Investig (Lond)., Nov;1(11):1533-1544 (2011)
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.
J. Natl. Cancer Inst., Sep;104(17):1320-34 (2012)
Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.
J. Med. Chem., Sep;55(17):7450-9 (2012)
Engineering enzymatically activated "molecular grenades" for cancer.
Oncotarget., Jul;3(7):666-7 (2012)
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Sci Transl Med., Jun;4(140):140ra86 (2012)
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Ann. Oncol., Oct;23(10):2714-9 (2012)
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
Prostate., Oct;72(14):1491-505 (2012)
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.
Mol. Cancer Ther., Feb;11(2):257-66 (2012)
Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.
Prostate., Aug;72(11):1233-8 (2012)
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Cancer Chemother. Pharmacol., Mar;69(3):763-71 (2012)
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.
Prostate., Nov;71(15):1595-607 (2011)
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.
Expert Rev Endocrinol Metab., Sep;5(5):753-764 (2010)